MHC分子に結合する腫瘍関連ペプチド

Japanese Patent JP5042303

B2

Tumor-associated peptides (I) having any of 79 sequences, reproduced, are new. (I) can bind to a Class I molecule of the human major histocompatibility complex (MHC). Independent claims are also included for the following: (1) nucleic acid (II) that encodes (I); (2) vector that contains (II); and (3) cell modified to express (I), by incorporation of (II) or the vector of (2). ACTIVITY : Cytostatic. MECHANISM OF ACTION : Vaccine; induction of cytotoxic T lymphocytes (CTL). Dendritic cells (0.5 million) were isolated from peripheral blood and incubated with peptide (1) at 50 mu g/ml for 2 hours, then washed and incubated with 2.5 million autologous peripheral blood mononuclear cells (PBMC) for 7 days. The cells were restimulated with interleukin-2 (1 ng/ml) on days 1, 3 and 5, then cytotoxicity tested against various cancer cells at effector:target ratio 30:1, in a standard 51chromium release assay. Typical specific lysis scores were over 30% for HCT 116 stomach cancer cells; over 60% for A498 renal cancer cells; about 40% for MEL1479 melanoma and about 50% for MCF-7 breast cancer cells. Tyr-Val-Asp-Pro-Val-Ile-Thr-Ser-Ile (1).

Weinschenk, Toni
Rammensee, Hans, Georg
Stevanovik, Stephan

JP2009283586A

October 03, 2012

December 15, 2009

Click for automatic bibliography generation  

Imatics Biotechnology GM Behr

C12N15/09; A61K38/00; A61K39/00; A61K39/395; A61P1/04; A61P1/18; A61P13/12; A61P15/00; A61P15/14; A61P35/00; A61P37/04; C07K7/06; C07K14/47; C07K14/82; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/12; G01N33/569; G01N33/574; G01N33/68; A61K48/00

WO2002086443A1

J. Biol. Chem.,1997年,272(41),25576-82
J. Lipid Res.,2001年,42(4),620-30
Cancer Res.,2002年10月15日,62,5818-27

Takashi Shoji

Previous Patent: ＭＨＣ分子に結合する腫瘍関連ペプチド

Next Patent: 土中の揮発性有機化合物を酸化させる方法